{"id":"NCT01304589","sponsor":"University of Tennessee","briefTitle":"Savella in Treatment for Provoked Vestibulodynia","officialTitle":"An Open Label Trial of Milnacipran in the Treatment of Women With Provoked Vestibulodynia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2012-09","completion":"2012-09","firstPosted":"2011-02-25","resultsPosted":"2014-04-02","lastUpdate":"2018-06-11"},"enrollment":31,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Vestibulodynia","Vulvodynia"],"interventions":[{"type":"DRUG","name":"Milnacipran","otherNames":["Savella"]}],"arms":[{"label":"Milnacipran","type":"EXPERIMENTAL"}],"summary":"The primary aim of this study is to determine the efficacy of milnacipran in reducing pain in women with provoked vestibulodynia (PVD), a centrally mediated pain syndrome similar to fibromyalgia, that is characterized by severe pain in the vestibule (outer vagina). The investigators will also determine whether associated symptoms in PVD, including psychological distress, impairment of sexual function, physical function, and quality of life, are correlated with a reduction in vulvar pain.","primaryOutcome":{"measure":"Pain Rating Index","timeFrame":"18 weeks","effectByArm":[{"arm":"Milnacipram","deltaMin":12.3,"sd":13.3}],"pValues":[{"comp":"OG000","p":".001"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":31},"commonTop":["nausea","headache","hot flashes","dizziness"]}}